Champignon Brands Inc.’s (OTCMKTS:SHRMF) CEO and Chairman Roger McIntyre has announced a Canadian Rapid Treatment Centre of Excellence clinic in Ottawa, Ontario. The CRTCE clinic is the third clinic the company is opening, joining the Toronto and Mississauga clinic in addressing the unmet suicide and depression need true ketamine therapy treatment.
Champignon bringing access to ketamine therapy to Canadian
CRTCE Medical Director Joshua Rosenblat said that over twenty clinics have shown that esketamine and ketamine have a quick and strong antidepressant effect in unresponsive patients to conventional antidepressants. Rosenblat added the pandemic increased the need for an effective antidepressant treatment as the number of people dealing with stress and depression increased. Most importantly, access to Ketamine treatment for depression in Canada is challenging, and according to Rosenblat, the new clinic will enhance treatment access.
Interestingly, CRTCE is the first of its king multidisciplinary outpatient clinical research facility specializing in the provision of breakthrough fast onset depression treatment. It includes intranasal esketamine and intravenous ketamine. These are important therapies helping patients dealing with treatment-resistant conditions like bipolar disorder and major depressive disorder. Nurse practitioners, physicians, and psychiatrists have to refer patients to receive treatment at CRTCE clinics.
Champignon publishes Bipolar Disorder article in The Lancet
Champignon Brands recently announced the publication of an article led by McIntyre titled “Bipolar Disorders” in The Lancet journal. The Lancet is a reputable scientific journal in medicine, and the article will contribute to the journal’s peer review seminars. It offers a “state-of-the-art overview of bipolar disorders, converting epidemiology, parthenogenesis, diagnosis, treatment, and prevention while highlighting relevant clinical controversies.
Mostly, bipolar disorders develop before 25 years is around 70% of individuals and significantly reduced the patient’s quality of life and psychosocial functioning. Bipolar individuals tend to show depressive symptoms and episodes, with around 1.25% of patients having major depressive disorders often diagnosed with bipolar disorders. Just like schizophrenia, the disorder reduces life expectancy by ten to twenty years, but in most cases, bipolar individuals are 20-30 times more likely to commit suicide.
